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Estrogens are risk factors for human breast cancer and induce kidney tumors in Syrian hamsters.
Mechanistic features of the estrogen-induced hamster kidney tumor model have been compared
with corresponding aspects of human breast cancer to gain insight into the mechanism of human
mammary oncogenesis. Shared characteristics point to a mechanism of metabolic activation of
steroidal estrogens to 4-hydroxylated catechol metabolites that may undergo metabolic redox
cycling, a mechanism of generation of reactive free radicals. Tumors may arise in cells genetically
altered by various types of estrogen-induced DNA damage. At the same time, these altered cells
may respond to estrogen receptor-mediated stimuli in support of cell transformation and growth.
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Estrogens and Breast Cancer
Estrogen administration is accepted by
most epidemiologists as a risk factor of
human endometrial adenocarcinoma (1,2).
Thus, estrogens unopposed by progestins
increase the risk of uterine tumors. This
risk increases with increasing doses of
estrogen and with the length of treatment
(3). Obesity also increases uterine tumor
risk, most likely because the aromatase
activity ofadipose cells elevates circulating
estrone levels (3,4).
Increasing evidence shows that elevated
levels of estrogens in the body are also a
risk factor in breast cancer. Exogenous
estrogens, alone or in combination with
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progestin, elevate breast cancer risk (5-7).
Progestin added to the estrogen medica-
tions does not inhibit mammary carcino-
genesis (8) because the former hormone
appears to be the primary mitogen of
mammary ductal epithelial cells (9),
whereas estrogen appears to function in
this manner in the uterus. This role of
estrogen in human breast carcinogenesis is
supported by risk factors ofbreast cancer
such as high serum or urine estrogen levels
(10,11), the early onset of menstruation,
or late menopause (12). These relation-
ships are illustrated by the fact that the
breast cancer risk of a woman undergoing
menopause at 45 years ofage is halfthat of
a woman experiencing menopause at 55
years ofage (5,6,12). These lines of evi-
dence indicate that the total lifetime
exposure of a woman to exogenous or
endogenous estrogen is a determinant of
her breast cancer risk.
Animal Models of Estrogen-
induced Cancer
For the examination of the mechanism of
estrogen-induced tumorigenesis, animal
models are needed in which steroidal estro-
gens induce tumors with high incidence.
There are very few reports in rodent mod-
els ofestrogen-induced mammary tumori-
genesis not mediated by hydrocarbon
carcinogens, viruses, or other initiating
agents. Estrogens induce or enhance tumor
formation in organs ofrodents such as the
uterus (13,14), pituitary (15,16), prostate
(17), uterine cervix (18), testes (19), and
liver (20). In addition, the estrogen-induced
kidney tumorigenesis in Syrian hamsters has
been used extensively for mechanistic
studies (21) because 100% tumor inci-
dence is routinely achieved using the nat-
ural hormone 17f-estradiol (E2) or estrone
without coadministration ofany other car-
cinogens. This animal model is useful for
mechanistic studies because the tumor is
estrogen induced and estrogen dependent,
because cell lines have been developed that
share growth characteristics with the pri-
mary tumor (22,23), and because the
tumor incidence may be manipulated by
coadministration ofother hormones such
as progesterone or testosterone (21).
Several synthetic steroidal estrogens
were only weakly carcinogenic in this
model system despite their powerful hor-
monal potencies (21,24,25). This lack of
correlation of estrogenic characteristics
with carcinogenic activities ofsteroids led
to the conclusion that hormonal potency
ofan estrogen was necessary but not suffi-
cient for tumor induction (24,25). It was
further concluded that metabolic activation
ofestrogens to reactive intermediates is a





The metabolic activation of estrogens to
catechol metabolites and further to reactive
semiquinone or quinone intermediates is a
central feature ofthis mechanistic proposal
and is analogous to the metabolic activa-
tion of many other carcinogens. The
primary metabolic conversion ofthe estro-
genic hormones estrone or E2 in liver of
most mammalian species is 2-hydroxyla-
tion, as shown for hamsters in Table 1
(26,27). However, an elevated formation
of4-hydroxyestrogen metabolites by spe-
cific estrogen-4-hydroxylases has been
detected in hamster kidney (28), mouse
uterus (29), and rat pituitary (30)-all
organs in which estrogens are known to
induce tumors (13-16,21). The elevated
formation of4-hydroxyestrogens in rodent
organs in which estrogens induce tumors
is significant because catecholestrogens,
including 4-hydroxyestrogens, may undergo
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Table 1. Microsome-mediated conversion of 10 pM E2to catechol metabolites in targets of estrogen-induced cancerand controls.a
Target 2-OH-E2, pmol/mg 4-OH-E2, protein/min 4-OH-E2/2-OH-E2 Reference
Hamster livercontrol 365.0 52.4 0.14 Weisz etal. (28)
Hamster kidney
Control 13.4 7.2 0.5 Weisz et al. (28)
E2-Treated 2.2 6.1 2.8
CD-1 mouse uterus
Control 0.1 1.3 13.0 Paria etal. (29)
Sprague-Dawley rat pituitary
Control 0.03 0.29 9.7 Bui andWeisz(30)
E2-Treated 0.08 0.24 3.0







Figure 1. Formation and redox cycling of 4-OH-E2. E2 is converted by cytochrome P450 enzymes, including P4501Bi, to 4-OH-E2, which may undergo metabolic redox cycling
between hydroquinone and quinone forms via semiquinone intermediates. The oxidation of this cycle is catalyzed mainly by organic hydroperoxide-dependent cytochrome
P4501A1 and the reduction by NADPH-dependent cytochrome P450 reductase. The semiquinone is a free radical that may react with molecular oxygen to form superoxide.
Detoxification pathways are phase 11 conjugation reactions of the catechol, including methylation by catechol-0-methyltransferase (COMT). Details are outlined in a recent
review byYager and Liehr (54).
metabolic redox cycling between hydro-
quinoneand quinone forms (Figure 1).
The catecholestrogen quinone inter-
mediates may form covalent DNA adducts
(31,32). Moreover, metabolic redox
cycling generates free radicals that are capa-
ble ofdirect or indirect covalent modifica-
tion of DNA (Figure 2) (33,34). In line
with this hypothesis, hydroxy radical dam-
age such as 8-hydroxyguanine bases of
DNA or DNA single strand breaks have
been detected in the kidney ofhamsters
treated with estradiol (35-37). In addi-
tion, intranuclear, site-specific redox
cycling involving catecholestrogen metabo-
lites and copper ions may induce DNA
damage by reactive oxygen, which is not
mediated bymetabolizing enzymes (38).
Lipid hydroperoxides (LHP) play a
central role in the DNAdamage process by
catechol estrogens (Figure 2). LHP are
formed by free radicals generated by redox
cycling. They, in turn, support redox
cycling as cofactors in the cytochrome
P4501A-mediated oxidation step ofthe
redox cycle (33,39). Finally, LHP may
decompose into reactive aldehydes such as
malondialdehyde, which covalendy bind to
DNA (40).
One or several of these classes of
covalent DNA damage may initiate and/or
promote the carcinogenic process (Figure
3). Tumors may develop from cells geneti-
cally altered by the processes outlined
above. At the same time, these altered cells
may respond to a receptor-mediated
proliferative stimulus either by estradiol or
by 4-hydroxyestradiol, which is known to
be along-acting estrogen (41).
MechanisticAnalogies in
Hamster and Human Breast
Despite the obvious differences arising from
the differences of organ system, cell type,
latency of tumor development, and other
factors, there are several common features
ofestrogen-induced kidney tumors in ham-
sters and human breast cancer (Table 2),
that point to the mechanistic pathway out-
lined above as a possible explanation of
human mammary oncogenesis. Elevated
urinary or serum estrogen levels in women
at risk ofbreast cancer indicate an inducing
role of estrogen in the carcinogenic process












Figure 2. Proposed pathways of DNA damage by metabolic activation of estrogens. In target tissues, 1
hormone E2 may be converted by NADPH- or LHP-dependent pathways (1 or 2, respectively) predon
4-OH-E2. This catecholestrogen metabolite may undergo metabolic redox cycling by LHP-dependent o)
the semiquinone and quinone catalyzed by cytochrome P4501A family enzymes (3). The quinone may t
by NADPH-dependent cytochrome P450 reductase (4) or by NADH-dependent quinone reductase (5) in a
tron reduction bypassing the semiquinone. The semiquinone may react with molecular oxygen to form
radicals, which are reduced to hydrogen peroxide by superoxide dismutase (6). H202 may be reduced by
to hydroxy radicals, which initiate the formation of LHP. DNA may be covalently modified byaldehyde d
tion products of LHP, by hydroxy radicals, or by covalent binding of quinone metabolites. Although 2
brackets), the mostcommon metabolite formed by liverenzymes, iscapable ofundergoing metabolic red
its contribution to free radical generation and DNA damage may be negligible because it is convertec
gates by phase 11 metabolism enzymes much more efficiently than the 4-hydroxylated isomer. The p
estrogen metabolites to damage cells is potentiated by redoxcycling and bythe initiation offree radical
Details ofthis pathway are outlined in a recent review byYagerand Liehr(54).
Table2. Shared characteristics ofhuman breast cancerand estrogen-induced hamsterkidneytumorigen
Mechanistic features Human breast, reference Hamsterkidney,
E2 as riskfactor/inducing agent Toniolo etal. (10); Kirkman (21)
Adlercreutz etal. (11);
Henderson etal.(12)
Specific 4-hydroxylation ofE2 Liehrand Ricci (43) Weisz etal.(28)
Increased 8-OH-dG bases in DNA Malins etal.(47) Han and Liehr(3
Single strand breaks of DNA Nutter etal.(53)a Han and Liehr(3
Elevated LHP levels Boyland and McGuire(48) Wang and Liehr
Increased malonaldehyde-DNA adducts Nath etal. (49); Wang etal. (50) Wang and Liehr
Tumor incidence decreased byvitamin C Howe etal. (51) LiehrandWheel
The induction of DNA single strand breaks by an estrogen metabolite has been demonstrated in MC
cancercells(53).
(10,11). However, not every woman with
high estrogen levels will develop this dis-
ease. Thus, an estrogen metabolite rather
than the parent hormone likely is the ulti-
mate carcinogenic factor. This reasoning is
supported by the elevated urinary catec-
holestrogen concentrations in women at
risk ofbreast cancer compared to controls
(11). Moreover, in microsomes of
breast cancer cells (42) and of
mammary fibroadenoma and ade
noma (43), 4-hydroxylation of e
strongly predominated over 2-hy
tion. This formation of4-hydroxye
in humans is mediated by a specific
activity, cytochrome P4501B1 (42
E 4-Hydroxylated _ Redox _ Free radical
2 O' CE cycling generation
ER-mediated ene Various
transformation, -4 Gee aiu types
growth Mutations of DNAdamage
Figure 3. Proposed mechanism of estrogen-induced
carcinogenesis. E2 is activated by hydroxylation to 4-
hydroxylated catecholestrogens (CE), their redox
cycling, and free radical generation as outlined above.
The various types of DNA damage generated by meta-
bolic activation of estrogens may induce gene muta-
tions. Tumors are proposed to arise in cells genetically
DNA altered by this estrogen-induced genotoxicity. At
adducts the same time, these altered cells may respond to
ER-mediated cell transformation and growth.
Thus, in target cells of mammary onco-
genesis, estradiol may be preferentially
converted to 4-hydroxyestradiol, which in
the hamster kidney tumor model is a car-
cinogenic metabolite of estradiol (46).
the natural Consistent with the pathway ofmetabolic
ninantly to activation and DNA damage outlined
xidation to above, elevated levels of8-hydroxyguanine
be reduced bases ofDNA (47), increased lipid peroxi-
two-elec- dation (48), and increased levels ofLHP-
superoxide derived aldehyde DNA adducts (49,50)
metal ions have been detected in mammary tissues of 'ecomposi- breast cancerpatients. The sameindicators
loxcycling ofindirect, estrogen-induced cell damage
d to conju- have been detected previously in hamsters
otential of and are listed in Table 2. Consistent with a
reactions. hypothesis oftumor initiation by estrogens,
vitamin C decreased mammary tumor inci-
dence in humans (51), as has been observed
iesis. previously in hamsters (52).
Conclusion reference
Complex interactions ofmetabolic, chemi-
cal, physiological, and endocrine effects of
estrogenic hormones are involved in the
induction of tumors in the breast. This
?6,37) complexity requires a multidisciplinary
5) design ofexperiments because emphasizing
(39) various aspects ofcarcinogenesis has not
er(52) sufficed to explain the full sequence of events resulting in the appearance ofmam- :F-7 breast mary tumors. The mechanisms outlined
above are complex and difficult to under-
stand, yet represent the best explanation to
MCF-7 date ofthe experimental data. Additional
human research into better animal models, into the
nocarci- relation ofestrogen metabolism to breast
stradiol cancer, and into better assays ofestrogen
droxyla- metabolites and metabolizing enzymes will
!strogens provide a more detailed understanding of
enzyme mammarycarcinogenesis.
'44,45).
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